“`html
Larimar Therapeutics (NASDAQ:LRMR), a clinical-stage biotech company, has scheduled a conference call and webcast for September 29, 2025, at 8:00 am EDT to discuss updates on their nomlabofusp clinical development program. The presentation will include data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia.
Larimar Therapeutics (NASDAQ:LRMR), una società biotech in fase clinica, ha programmatico una conference call e webcasting per il 29 settembre 2025 alle 8:00 EDT per discutere aggiornamenti sul programma di sviluppo clinico di nomlabofusp. La presentazione includerà dati dallo studio open-label a lungo termine in corso per il trattamento della atassia di Friedreich.
Larimar Therapeutics (NASDAQ:LRMR), una empresa biotecnológica en etapa clínica, ha programado una llamada de conferencia y webcast para el 29 de septiembre de 2025 a las 8:00 a.m. EDT para discutir actualizaciones sobre su programa de desarrollo clínico de nomlabofusp. La presentación incluirá datos del estudio abierto a largo plazo en curso para el tratamiento de la atrofia de Friedreich.
Larimar Therapeutics (NASDAQ:LRMR)는 임상 단계의 생명공학 회사로, 2025년 9월 29일 동부 표준시 오전 8:00에 nomlabofusp 임상 개발 프로그램의 업데이트를 논의하기 위한 전화회의 및 웹캐스트를 예정했습니다. 발표에는 진행 중인 장기 개방-label 연구의 프리드라이히 실조증(Friedreich의 실조증) 치료에 대한 데이터가 포함될 것입니다.
Larimar Therapeutics (NASDAQ: LRMR), une société biotechnologique en phase clinique, prévoit une conférence téléphonique et un webcast pour le 29 septembre 2025 à 8h00 EDT afin de discuter des mises à jour sur leur programme de développement clinique de nomlabofusp. La présentation comprendra des données de l’étude ouverte à long terme en cours pour le traitement de l’ataxie de Friedreich.
Larimar Therapeutics (NASDAQ:LRMR), ein klinisch-phasenbiotech-Unternehmen, hat eine Telefonkonferenz und einen Webcast für den 29. September 2025 um 8:00 Uhr EDT angekündigt, um Aktualisierungen zum klinischen Entwicklungsprogramm von nomlabofusp zu diskutieren. Die Präsentation enthält Daten aus der laufenden Langzeit-Open-Label-Studie zur Behandlung von Friedreich-Ataxie.
Larimar Therapeutics (NASDAQ:LRMR)، شركة تقنية حيوية في طور سريري، حددت مكالمة مؤتمرات وبثاً مباشراً عبر الويب لـ 29 سبتمبر 2025 الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة لمناقشة التحديثات حول برنامج التطوير السريري لـ nomlabofusp. ستتضمن العرض بيانات من الدراسة المفتوحة طويلة الأجل الجارية لعلاج التررنّح المرتبط بمرض فريدريش.
Larimar Therapeutics (NASDAQ:LRMR)，一家处于临床阶段的生物技术公司，已安排于 2025年9月29日美国东部夏令时早上8点举行电话会议和网络直播，以讨论其 nomlabofusp 的临床开发计划的最新进展。演示将包含正在进行的长期开放标签研究中关于治疗 弗里德赖希共济失调（Friedreich’s ataxia）的数据。
09/28/2025 – 05:00 PM
Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDT
BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced it will be holding a conference call and webcast to discuss updates to its nomlabofusp clinical development program. This includes data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia, scheduled for Monday, September 29, 2025 at 8:00 am EDT.
This event comes at a critical juncture for Larimar as it seeks to demonstrate the long-term efficacy and safety profile of nomlabofusp in patients with Friedreich’s ataxia (FA), a debilitating genetic disease that progressively damages the nervous system. Analysts are keenly watching the data, as positive results could significantly de-risk the program and potentially expedite regulatory pathways.
**Conference Call and Webcast Details**
Investors and interested parties can access the webcast via this link. Those preferring to participate by phone can dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13756144.
Following the live event, an archived webcast will be made available on the “Events & Presentations” page of the Larimar website.
**Nomlabofusp: A Closer Look at the Science**
Nomlabofusp’s mechanism of action is designed to address the underlying cause of FA, which is a deficiency in the frataxin protein. The drug aims to increase frataxin levels within cells, potentially mitigating the effects of the disease. The long-term open-label study is crucial for assessing the drug’s durability of effect and identifying any potential long-term safety concerns.
**Market Opportunity and Competitive Landscape**
Friedreich’s ataxia represents a significant unmet medical need, with limited treatment options currently available. Larimar is positioning nomlabofusp as a potentially disease-modifying therapy. Success in clinical trials could translate to a substantial market opportunity, but the company will need to navigate competitive pressures from other emerging therapies in the FA space. Any future regulatory approval could give Larimar a significant edge over its competitors which include companies focusing on alternative approaches such as gene therapy and other protein modulation technologies.
**About Larimar Therapeutics**
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to leverage its intracellular delivery platform to design other fusion proteins targeting additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
For more information, please visit: https://larimartx.com.
**Forward-Looking Statements**
This press release contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar’s planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding potential for accelerated approval or accelerated access and time to market and overall development plans and other matters regarding Larimar’s business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar’s product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later clinical trials, and assessments; that the FDA may not ultimately agree with Larimar’s nomlabofusp development strategy; the potential impact of public health crises on Larimar’s future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar’s ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp’s manufacturing process; Larimar’s ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar’s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar’s management’s views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.
FAQ
When is Larimar Therapeutics (LRMR) hosting its conference call about nomlabofusp?
Larimar Therapeutics is hosting the conference call on Monday, September 29, 2025 at 8:00 am EDT.
What will be discussed in Larimar Therapeutics’ (LRMR) September 2025 conference call?
The call will discuss updates for the nomlabofusp clinical development program, including data from the ongoing long-term open label study for treating Friedreich’s ataxia.
How can investors access Larimar Therapeutics’ (LRMR) September 2025 conference call?
Investors can access the webcast through a provided link or dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) with conference ID 13756144.
Where can I find the replay of Larimar Therapeutics’ (LRMR) September 2025 conference call?
An archived webcast will be available on the ‘Events & Presentations’ page of the Larimar website following the live event.
